Lois E Shepherd

Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.

Dongsheng Tu, Martine J Piccart, James N Ingle, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Daniel J Sargent, Dongsheng Tu, Pierre Laurent-Puig, 2003, The New England journal of medicine.

Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.

Naiqing Zhao, Dongsheng Tu, P. Goss, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

Robert B Livingston, Dongsheng Tu, Jeffrey S Abrams, 2005, Journal of the National Cancer Institute.

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

Irene L Andrulis, Dongsheng Tu, I. Andrulis, 2006, The New England journal of medicine.

Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.

Karen A Gelmon, James N Ingle, Vered Stearns, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.

Dongsheng Tu, Nancy Paul, D. Tu, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.